Abstracts tagged "prognostic factors"

Abstract Number: 2444 • ACR Convergence 2024
Performance of the DETECT Algorithm and Cluster Analysis in Screening for Systemic Sclerosis Pulmonary Hypertension Groups
Ryan Osgueritchian¹, Hoda Mombeini¹, Vivek Jani², Adrianne Woods³, Steven Hsu¹, Matthew Lammi⁴, Paul Hassoun⁴, Fredrick Wigley⁵, Laura Hummers⁶, Stephen Mathai⁷, Ami Shah⁸ and Monica Mukherjee¹, ¹Johns Hopkins University Division of Cardiology, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University Division of Rheumatology, Baltimore, MD, ⁴Johns Hopkins University Division of Pulmonary and Critical Care Medicine, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁷Johns Hopkins University Division of Pulmonary and Critical Care Medicine,, Blatimore, ⁸Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Pulmonary hypertension (PH) portends poor outcomes in Systemic Sclerosis (SSc). Recent efforts for early identification and intervention in SSc patients with pulmonary arterial hypertension…
Abstract Number: 0559 • ACR Convergence 2024
Predicting Disease Flares in Axial Spondyloarthritis Using Machine Learning in the METEOR-SpA Registry
Diego Benavent¹, Victor Fanjul², Sytske Anne Bergstra³, Floris van Gaalen⁴, Maxime Dougados⁵, Umut Kalyoncu⁶, Denis Poddubnyy⁷, Clementina López Medina⁸, Konstantinos Parperis⁹, David Vega-Morales¹⁰, Desiree van der Heijde¹¹ and Victoria Navarro Compán¹², ¹Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, ²Savana Research, Madrid, ³LUMC, Leiden, Netherlands, ⁴LUMC, Leiden, Zuid-Holland, Netherlands, ⁵Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁶Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁷Charite-Universitatsmedizin Berlin, Berlin, Germany, ⁸Reina Sofia University Hospital, Cordoba, Spain, ⁹University of Cyprus Medical School, Nicosia, Cyprus, ¹⁰Instituto Mexicano del Seguro Social, Monterrey, México, Monterrey, Mexico, ¹¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain
Background/Purpose: Patients with axial spondyloarthritis (axSpA) frequently experience unforeseen disease flares that impact their quality of life. Identification of patients with high risk of flares…
Abstract Number: 1498 • ACR Convergence 2024
Gender Disparities in Clinical Manifestations and Outcomes of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mazen Allouni¹, Muhammad Shamim², Krista Topalsky³ and Omer Pamuk⁴, ¹Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ²University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ³University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: The clinical manifestations and outcomes of systemic lupus erythematosus (SLE) reveal notable gender differences, which may impact treatment strategies and patient outcomes. This meta-analysis…
Abstract Number: 2450 • ACR Convergence 2024
Disease Progression in Anti-Centromere Positive Systemic Sclerosis Patients
Eva Hoekstra¹, S. Ahmed², David Ueckert³, Nina Ajmone Marsan³, Philippine Kiès³, M.K. Ninaber³, Marlies Heuvers³, Miranda Geelhoed³, Thomas Huizinga⁴ and Jeska de Vries-Bouwstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Leids Universitair Medisch Centrum, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Disease progression in systemic sclerosis (SSc) is characterized by severe and early progression in anti-topoisomerase (ATA) positive diffuse cutaneous patients and typically involves lung…
Abstract Number: 0574 • ACR Convergence 2024
14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study
Anthony Marotta¹, Walter Maksymowych², Stephanie Wichuk² and Navneet Sidhu¹, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: Diagnosis of axial spondyloarthritis (AxSpA) is challenging and often delayed primarily due to the lack of sensitive and specific markers needed for accurate and…
Abstract Number: 1590 • ACR Convergence 2024
Milder ILD with Preserved Lung Function Significantly Contributes to Respiratory Caused Mortality in SSc
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim¹, Emily Langballe², Hilde Jenssen Bjørkekjær³, Henriette Didriksen¹, Phuong Phuong Diep⁴, Anna Helena Andersson¹, Ragnar Gunnarsson¹, Michael T Durheim¹, Torhild Garen¹, Øyvind Midtvedt⁵, Trond Mogens Aaløkken⁶, Øyvind Molberg⁷ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ³Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, ⁴Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, ⁵Oslo University Hospital, Oslo, Oslo, Norway, ⁶Medicine, Oslo, Norway, Oslo, Norway, ⁷Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is the main cause of death in systemic sclerosis (SSc). While impaired lung function with forced vital capacity (FVC) <…
Abstract Number: 2451 • ACR Convergence 2024
Prognostic Value of Functional Outcomes in a Italian Multicentric Cohort of Early SSc-ILD Patients
Chiara Bellocchi¹, Alessandro Santaniello², Silvia Bosello³, Enrico De Lorenzis⁴, Gerlando Natalello⁵, Nicoletta Del Papa⁶, Silvia Cavalli⁷, Devis Benfaremo⁸, Giacomo De Luca⁹, Corrado Campochiaro¹⁰, Lorenzo Cavagna¹¹, Veronica Codullo¹², Francesco Bonomi¹³, gaia Montanelli¹⁴, Adriana Severino¹⁵, Monica Caronni², Martina Iacubino¹⁶, Barbara Vigone², Silvia Bellando-Randone¹⁷, Carlomaurizio Montecucco¹⁸, Marco Matucci-Cerinic¹⁹, Lorenzo Dagna²⁰, Gianluca Moroncini⁸, Roberto Caporali²¹ and Lorenzo Beretta²², ¹Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, MILANO, Italy, ³FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI- IRCCS, Rome, Rome, Italy, ⁴Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁶ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milano, Milan, Italy, ⁷University of Milan, Milan, Milan, Italy, ⁸Marche Polytechnic University, Ancona, Italy, ⁹Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁰IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹¹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ¹²Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ¹³Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Milan, Italy, ¹⁶Università degli Studi di Milano, Milano, Italy, ¹⁷University of Florence, Florence, Florence, Italy, ¹⁸IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ¹⁹University San Raffaele Milano, Milano, Milan, Italy, ²⁰Ospedale San Raffaele, Milano, Italy, ²¹Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²²Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc). Pulmonary function tests (PFTs) can serve as useful surrogate measures…
Abstract Number: 0580 • ACR Convergence 2024
Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis
Ayantika Talukdar¹, Neke Ibeh², Rohan Machhar², Mansi Aparnathi³, Sareh Keshavarazi⁴, Archita Srinath⁵, Akihiro Nakamura⁶, Robert Inman⁷, Proton Rahman⁸, Igor Jurisica⁹ and Nigil Haroon¹⁰, ¹Krembil Research Institute, UHN, Toronto, ON, Canada, ²UHN, Toronto, Canada, ³University Health Network, Toronto, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Queen's Univesity, Kingston, ON, Canada, ⁷University Health Network, Toronto, ON, Canada, ⁸Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, ⁹Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, ¹⁰Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) substantially improve symptoms in Ankylosing Spondylitis (AS), although 40% patients are unresponsive. Identifying biomarkers predictive of TNFi treatment response…
Abstract Number: 1624 • ACR Convergence 2024
Prognostic Value of Baseline 18F-FDG PET/CT Scan in Giant Cell Arteritis with Large Vessel Involvement
Julio Sánchez-Martín¹, Javier Loricera², Isabel Martinez-Rodriguez³, ivan Ferraz-Amaro⁴, Nestor Martinez-Amador⁵, Remedios Quirce-Pisano⁵, Fernando Lopez-Gutierrez⁶ and Ricardo Blanco-Alonso⁷, ¹Hospital Universitario 12 de Octubre, Madrid, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Nuclear Medicine, Hospital Universitario Marques de Valdecilla,IDIVAL, Santander, Cantabria, Spain, ⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁵Department of Nuclear Medicine, Hospital Universitario Marqués de Valdecilla, Molecular Imaging Group, IDIVAL, Santander., Santander, Spain, ⁶Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan has become a very useful diagnostic tool in patients with GCA with large vessel involvement. However,…
Abstract Number: 2471 • ACR Convergence 2024
Association of Telangiectasias with Autoantibodies and Clinical Manifestations in Systemic Sclerosis
Namitha Nair¹, Thomas Medsger, Jr², Robert Lafyatis³, Maureen Laffoon⁴, Leigh Freno⁴ and Robyn Domsic⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ³University of Pittsburgh, Pittsburgh, PA, ⁴UPMC, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Telangiectasias (Tel) are visibly dilated cutaneous post-capillary venules reported to occur in about 75% of patients with systemic sclerosis (SSc), making them a common…
Abstract Number: 0623 • ACR Convergence 2024
Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus
Melissa Munroe¹, Daniele DeFreese², Adrian Holloway², Mohan Purushothaman², Wade DeJager³, Susan Macwana³, Joel Guthridge⁴, Stan Kamp³, Nancy Redinger³, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yanfeng Li⁵, hu Zeng⁵, Uma Thanarajasingam⁵, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester
Background/Purpose: We have recently validated a plasma Lupus Flare Risk Index (L-FRI; Munroe et al. Ann Rheum Dis. 2024. 83 [Supp 1]: 402) and Lupus…
Abstract Number: 1629 • ACR Convergence 2024
Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica Has a Different Vascular Ultrasound Phenotype Than Giant Cell Arteritis
Sharon Cowley¹, Patricia Harkins², Colm Kirby³, Richard Conway⁴, David Kane⁵, Rositsa Karalilova⁶, Pierluigi Macchioni⁷, Christina Ponte⁸, Edoardo Conticini⁹, Alessandro Tomelleri¹⁰, Sara Monti¹¹, irene monjo¹², Zguro Batalov¹³, Giulia Klinowski⁷, Paolo Falsetti¹⁴, Corrado Campochiaro¹⁵, Alojzija Hocevar¹⁶ and Eugenio De Miguel¹⁷, ¹Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, ²Trinity College Dublin, Dublin 8, Dublin, Ireland, ³Tallaght University Hospital, DUBLIN, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, D24, Ireland, ⁶Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, Plovdiv, Bulgaria, ⁷Rheumatology Department, Ospedale S Maria Nuova, Reggio Emilia, Italy, Emilia, Italy, ⁸Rheumatology, Centro Hospitalar Universitario Lisboa Norte EPE, Lisboa, Portugal, Lisboa, Portugal, ⁹Università di Siena, Siena, Italy, ¹⁰Unit of Immunology, Allergology and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy, ¹¹IRCCS Istituto Auxologico Italiano, Milan, Italy, ¹²University Hospital La Paz, Madrid, Spain, ¹³Rheumatology, University Hospital Kaspela, Plovdiv, Bulgaria, Plovdiv, Bulgaria, ¹⁴Department of Medical Sciences, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Siena, Italy, Siena, Italy, ¹⁵IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹⁶University Medical Center Ljubljana, LJUBLJANA, Slovenia, ¹⁷Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Subclinical GCA in PMR has been estimated to affect 1 in 5 patients as assessed by vascular ultrasound [1, 2]. This study compared the ultrasound…
Abstract Number: 2475 • ACR Convergence 2024
The Critical Role of Annual HRCT in Identifying ILD Progression and Assessing Outcome in SSc
Anna-Maria Hoffmann-Vold¹, Simon Beyeler², Liubov Petelytska³, Håvard Fretheim¹, Trond Mogens Aaløkken⁴, Mike Becker⁵, Hilde Jenssen Bjørkekjær⁶, Cathrine Brunborgg¹, Cosimo Bruni⁷, Christian Clarenbach⁸, Phuong Phuong Diep⁹, Rucsandra Dobrota⁷, Michael T Durheim¹, Muriel Elhai¹⁰, Thomas Frauenfelder⁸, Suzana Jordan⁷, Emily Langballe¹¹, Øyvind Midtvedt¹², Carina Mihai⁷, Adela Sarbu⁸, Marco Sprecher⁸, Øyvind Molberg¹³ and Oliver Distler¹⁴, ¹Oslo University Hospital, Oslo, Norway, ²University Hospital Zurich, Zürich, Zurich, Switzerland, ³University Hospital Zurich, Zurich, Switzerland, ⁴Medicine, Oslo, Norway, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶Department of Rheumatology, Hospital of Southern Norway, Kristiansand, Kristiansand, Norway, ⁷University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸University Hospital Zurich, Zurich, Zurich, Switzerland, ⁹Oslo University Hospital, Department of Respiratory Disease, Oslo, Norway, ¹⁰University Hospital zurich, Zürich, Switzerland, ¹¹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ¹²Oslo University Hospital, Oslo, Oslo, Norway, ¹³Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc). Monitoring with lung function testing every 3–6 months for…
Abstract Number: 0683 • ACR Convergence 2024
Prognostic Value of Systemic Sclerosis-associated Primary Heart Involvement
Caya Gharibian¹, Vanessa Lupi¹, Alexander Gotschy¹, Mike Becker², Rucsandra Dobrota¹, Muriel Elhai³, Sinziana Muraru¹, Suzana Jordan¹, Anna-Maria Hoffmann-Vold⁴, Oliver Distler⁵, Robert Manka¹, Cosimo Bruni¹ and Carina Mihai¹, ¹University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³University Hospital zurich, Zürich, Switzerland, ⁴Oslo University Hospital, Oslo, Norway, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: A definition of primary heart involvement (pHI) in systemic sclerosis (SSc) was recently developed (Bruni C et al. J Scleroderma Relat Disord. 2022;7:24-32). Cardiac…
Abstract Number: 1693 • ACR Convergence 2024
Change in Forced Vital Capacity at Week 12 or 24 Has Prognostic Value for Outcome at Week 52 in Patients with Autoimmune Disease-Related Interstitial Lung Diseases
Anna-Maria Hoffmann-Vold¹, Margarida Alves², Corinna Miede³ and Oliver Distler⁴, ¹Oslo University Hospital, Oslo, Norway, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ³mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach, Germany, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Clinical trials in patients with interstitial lung diseases (ILDs) generally include a 52-week treatment period. Shorter trials would help speed up drug development and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].